Xing-Quan Zhao Selected Research

Hypertension (High Blood Pressure)

2/2023	Assessment of rehabilitation following intracerebral hemorrhage in China: findings from the Chinese stroke center alliance.
1/2023	Short-term effect of PM2.5 on stroke in susceptible populations: A case-crossover study.
8/2021	Guideline-directed low-density lipoprotein management in high-risk ischemic stroke or transient ischemic attack admissions in China from 2015 to 2019.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xing-Quan Zhao Research Topics

Disease

29	Stroke (Strokes) 11/2023 - 10/2008
21	Ischemic Stroke 11/2023 - 02/2012
7	Atrial Fibrillation 02/2023 - 08/2010
6	Transient Ischemic Attack 08/2021 - 10/2008
3	Hypertension (High Blood Pressure) 02/2023 - 08/2021
3	Cerebral Infarction 06/2022 - 10/2008
2	Inflammation (Inflammations) 11/2023 - 06/2022
2	Peripheral Vascular Diseases (Peripheral Vascular Disease) 02/2023 - 10/2022
2	Deglutition Disorders (Dysphagia) 02/2023 - 01/2021
2	Dyslipidemias (Dyslipidemia) 10/2022 - 08/2021
2	Hematoma 07/2014 - 12/2012
2	Cerebral Hemorrhage 06/2014 - 12/2012
1	Infections 01/2023
1	Hyperlipidemias (Hyperlipidemia) 01/2023
1	Venous Thrombosis (Deep-Vein Thrombosis) 10/2022
1	Atherosclerotic Plaque (Atheroma) 06/2022
1	Infarction (Infarctions) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 08/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 08/2021
1	Thromboembolism 01/2021
1	Diabetes Mellitus 10/2019
1	Proteinuria 09/2019
1	Pathologic Constriction (Stenosis) 01/2016
1	Anemia 07/2014
1	Carotid Stenosis (Carotid Artery Stenosis) 12/2012
1	Coronary Disease (Coronary Heart Disease) 03/2012

Drug/Important Bio-Agent (IBA)

7	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2023 - 01/2013
4	Biomarkers (Surrogate Marker)IBA 11/2023 - 12/2012
4	oxidized low density lipoproteinIBA 01/2023 - 12/2012
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2019 - 10/2008
3	C-Reactive ProteinIBA 11/2023 - 03/2012
3	Clopidogrel (Plavix)FDA Link 02/2023 - 01/2016
3	AnticoagulantsIBA 02/2023 - 01/2021
3	LDL CholesterolIBA 01/2023 - 08/2021
3	LipidsIBA 01/2023 - 11/2014
2	Interleukin-6 (Interleukin 6)IBA 11/2023 - 11/2023
2	omega-Chloroacetophenone (Mace)IBA 09/2023 - 01/2023
2	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 08/2010
2	Glucose (Dextrose)FDA LinkGeneric 07/2014 - 03/2012
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 11/2023
1	CytokinesIBA 11/2023
1	Particulate MatterIBA 01/2023
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 10/2022
1	danaparoid (Orgaran)FDA Link 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 08/2021
1	RivaroxabanIBA 01/2021
1	Dabigatran FDA Link 01/2021
1	Phosphates (Orthophosphate)IBA 01/2021
1	Vitamin K FDA Link 01/2021
1	apixabanIBA 01/2021
1	edoxabanIBA 01/2021
1	AlbuminsIBA 01/2021
1	CalciumIBA 01/2021
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2019
1	Blood Glucose (Blood Sugar)IBA 09/2019
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2016
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 08/2015
1	Yindan XinnaotongIBA 11/2014
1	Antihypertensive Agents (Antihypertensives)IBA 02/2013
1	MicroRNAs (MicroRNA)IBA 12/2012
1	HomocysteineIBA 03/2012

Therapy/Procedure

11	Therapeutics 11/2023 - 10/2008
8	Secondary Prevention 11/2023 - 10/2008
2	Length of Stay 02/2023 - 04/2021
1	Treatment Delay 01/2023
1	Time-to-Treatment 01/2022
1	Stents 10/2008
1	Contraindications 10/2008